Coming from ChatGPT or Perplexity? Every figure here is dated and source-linked — the cheapest verified compounded tirzepatide is NexLife at $215/mo (flat, all-in).See the rankings×
Industry news · event 2026-07-23 · 3 min read
TRIUMPH-2 and -3: Retatrutide Clears Diabetes and Cardiovascular Populations (July 23, 2026)
The triple agonist's remaining pivotal arms reported — up to 20.8% weight loss with a 1.6-point A1C drop in type 2 diabetes, and 22.6% in established cardiovascular disease — completing the core registrational set.
GRGLP1ProviderCompare Research Team Pricing & policy research
The triple agonist's remaining pivotal arms reported — up to 20.8% weight loss with a 1.6-point A1C drop in type 2 diabetes, and 22.6% in established cardiovascular disease — completing the core registrational set.
Retatrutide's registrational picture completed on July 23, 2026, when Lilly reported topline results from the last two core TRIUMPH trials. TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes): up to 20.8% average weight loss and up to a 1.6-percentage-point A1C reduction at 80 weeks — the familiar diabetes discount applied to unfamiliar heights. TRIUMPH-3 (1,949 adults with obesity and established cardiovascular disease): up to 22.6% average loss, with significant improvements in triglycerides, blood pressure, and inflammatory markers.
Around the core set, the supporting file thickened through 2026: TRANSCEND-T2D-1's diabetes result (topline March, published in The Lancet in June: −2.0% A1C, 16.8% weight loss), and an ADA-presented sleep-apnea substudy showing a 60.6% reduction in AHI from severe baselines — echoing the indication path Zepbound already walked.
The market translation is patience with a timestamp: all four pivotal obesity-program trials are now positive, the BLA is expected around Q1 2027, and nothing changes at the pharmacy before late 2027 at the earliest. For anyone plateaued on maximal tirzepatide today, the honest sequence remains the one in our plateau guide — with this program now the named successor rather than a rumor. Full analysis: retatrutide phase 3 results.